Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

741. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection

Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection Hay J W, Daum R S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Strategies for the prevention of Haemophilus influenzae type b. Type of intervention Primary prevention. Economic study type Cost-benefit analysis. Study population Hypothetical cohort of children. Setting The study was carried out in the USA. Dates to which data relate Price related to 1985. Source of effectiveness data Review of studies and opinions. Modelling

NHS Economic Evaluation Database.1987

742. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin.

Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. 2442610 1987 10 22 1987 10 22 2007 11 14 0028-4793 317 15 1987 Oct 08 The New England journal of medicine N. Engl. J. Med. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. 923-9 Apache Indian infants have a high frequency of Haemophilus influenzae type b (Hib) and pneumococcal (...) infections. Forty percent of Hib infections in these infants occur before the age of six months, when active immunization may not be protective. To evaluate the efficacy of passive immunization with a human hyperimmune globulin (bacterial polysaccharide immune globulin [BPIG]) prepared from the plasma of immunized adult donors, we randomly assigned 703 infants in a double-blind fashion to receive 0.5 ml of BPIG per kilogram of body weight (n = 353) or 0.5 ml of saline (n = 350) intramuscularly at 2, 6

NEJM1987

743. Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease.

Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. 2867396 1986 01 29 1986 01 29 2015 06 16 0140-6736 2 8469-70 1985 Dec 21-28 Lancet (London, England) Lancet Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. 1395-7 Fifty patients with chronic obstructive lung disease were randomly allocated to three groups, to assess whether an oral (...) vaccine containing non-typable Haemophilus influenzae protected against acute bronchitis. The double-blind prospective study over a three-month winter period included two placebo groups and one test group. Oral immunisation with H influenzae induced a tenfold reduction in the incidence of infection (p less than 0.001). During the subsequent winter, without further immunisation, protection by the vaccine was no longer statistically significant. There was no clear correlation between clinical protection

Lancet1986

744. Influenza A prophylaxis with amantadine in a boarding school.

Influenza A prophylaxis with amantadine in a boarding school. 6142218 1984 04 10 1984 04 10 2016 11 23 0140-6736 1 8375 1984 Mar 03 Lancet (London, England) Lancet Influenza A prophylaxis with amantadine in a boarding school. 502-4 In a boarding school for boys, where routine influenza vaccination is carried out annually, 267 boys were given amantadine (100 mg daily) and 269 received no specific treatment during an influenza A (H1N1) outbreak. 3 boys receiving amantadine and 29 boys receiving (...) no medication had laboratory-proven influenza A. There are circumstances when the prophylactic use of amantadine may be justified for the control of influenza A outbreaks in boarding schools and other institutions where high attack-rates are experienced. Payler D K DK Purdham P A PA eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Influenza Vaccines BF4C9Z1J53 Amantadine AIM IM Administration, Oral Adolescent Adult Amantadine administration & dosage

Lancet1984

745. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection.

Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. 6143042 1984 05 04 1984 05 04 2015 06 16 0140-6736 1 8379 1984 Mar 31 Lancet (London, England) Lancet Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. 705-8 The efficacy of live attenuated cold-adapted (ca) reassortant influenza virus vaccine against experimental (...) intramuscularly, provided 72% protection. Wild-type virus was recovered from only 13% of live virus vaccinees (10(7.5) TCID50 dose of ca virus) compared with 63% of inactivated virus vaccinees and the few infected live virus vaccinees shed 1000 times less wild-type virus than did infected inactivated virus vaccinees or unvaccinated controls. This striking reduction in virus shedding suggests that influenza transmission may be more efficiently interrupted with live than with inactivated virus vaccination

Lancet1984

746. Prevention of Hemophilus influenzae type b disease.

Prevention of Hemophilus influenzae type b disease. 6368889 1984 05 18 1984 05 18 2016 10 17 0098-7484 251 18 1984 May 11 JAMA JAMA Prevention of Hemophilus influenzae type b disease. 2381-6 To determine the efficacy of rifampin prophylaxis in eradication of oropharyngeal carriage of Hemophilus influenzae type b and prevention of secondary H influenzae type b disease, we conducted a multicenter placebo-controlled trial among selected persons with invasive H influenzae type b disease. Households (...) and day-care classrooms were randomized so that their members received either rifampin (initially at a dose of 10 mg/kg/dose for two to four days [rifampin-10], but subsequently at 20 mg/kg/dose for four days [rifampin-20]) or placebo. Pretherapy H influenzae type b colonization rates were similar in the treatment groups. Therapy with either rifampin regimen significantly reduced carriage (rifampin-20, 97%; rifampin-10, 63%; placebo, 28%). New acquisition of carriage was also significantly reduced

JAMA1984

747. Ribavirin aerosol treatment of influenza B virus infection.

Ribavirin aerosol treatment of influenza B virus infection. 6341642 1983 06 10 1983 06 10 2016 10 17 0098-7484 249 19 1983 May 20 JAMA JAMA Ribavirin aerosol treatment of influenza B virus infection. 2671-4 In a randomized, controlled study, ribavirin small-particle aerosol was found to be effective in the treatment of influenza B virus infection in a group of college students. Eleven treated patients experienced significantly more rapid defervescence, disappearance of systemic illness (...) HHS United States Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. United States JAMA 7501160 0098-7484 0 Aerosols 0 Antibodies, Viral 0 Ribonucleosides 451W47IQ8X Sodium Chloride 49717AWG6K Ribavirin AIM IM Adult Aerosols Antibodies, Viral analysis Clinical Trials as Topic Female Humans Influenza, Human drug therapy Male Nasal Mucosa microbiology Orthomyxoviridae immunology isolation & purification

JAMA1983

748. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection.

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. 7050702 1982 10 12 1982 10 12 2013 11 21 0028-4793 307 10 1982 Sep 02 The New England journal of medicine N. Engl. J. Med. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. 580-4 Four hundred fifty volunteers participated in a placebo-controlled, double-blind, randomized trial of the prophylactic effects of rimantadine and amantadine during an outbreak (...) of influenza A. The subjects received drugs orally at a dose of 100 mg twice a day for six weeks. Influenza-like illness occurred in 41 per cent of the subjects receiving placebo but in only 14 per cent of those receiving rimantadine and 9 per cent of these receiving amantadine (P less than 0.001 for either drug vs. placebo). Laboratory-documented influenza occurred in 21 per cent of placebo recipients, 3 per cent of rimantadine recipients, and 2 per cent of amantadine recipients (P less than 0.001

NEJM1982

749. Safety and immunogenicity of a new Haemophilus influenzae type b vaccine in infants under one year of age.

Safety and immunogenicity of a new Haemophilus influenzae type b vaccine in infants under one year of age. 6116855 1981 12 15 1981 12 15 2015 06 16 0140-6736 2 8249 1981 Oct 03 Lancet (London, England) Lancet Safety and immunogenicity of a new Haemophilus influenzae type b vaccine in infants under one year of age. 705-9 64 healthy infants 2-3 months old, were randomly assigned to one of three vaccination groups which received either diphtheria-pertussis-tetanus (DPT) vaccine, Haemophilus influenzae (...) the level assumed to give protection against invasive H. influenzae type b disease (greater than or equal to 0.15 microgram/ml). In contrast, less than 10% of the infants who received PRP vaccine alone showed 2-fold or greater increases. King S D SD Ramlal A A Wynter H H Moodie K K Castle D D Kuo J S JS Barnes L L Williams C L CL eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Antibodies, Bacterial 0 Antigens, Bacterial 0 Diphtheria

Lancet1981

750. Ribavirin small-particle aerosol treatment of influenza.

Ribavirin small-particle aerosol treatment of influenza. 6117726 1982 01 20 1982 01 20 2015 06 16 0140-6736 2 8253 1981 Oct 31 Lancet (London, England) Lancet Ribavirin small-particle aerosol treatment of influenza. 945-9 In an outbreak of influenza virus A/England/333/80(H1N1) infections in college students, 14 randomly selected patients were treated by inhalation of ribavirin small-particle aerosol through a face mask. They retained an average estimated 1.15 g of drug in 23 h of treatment (...) given over 3 days. 17 patients served as controls. Ribavirin aerosol treatment had a therapeutic effect judged by the highly significant reduction in height and duration of fever, reduction in systemic illness, and disappearance of influenza virus from respiratory secretions. 1 additional patient with influenzal pneumonia caused by a strain of influenza virus A/Bangkok/79(H3N2) recovered promptly with ribavirin aerosol treatment. Knight V V McClung H W HW Wilson S Z SZ Waters B K BK Quarles J M JM

Lancet1981

751. Rifampin prophylaxis for contacts of Haemophilus influenzae type b disease.

Rifampin prophylaxis for contacts of Haemophilus influenzae type b disease. 6970272 1981 04 24 1981 04 24 2016 10 17 0098-7484 245 10 1981 Mar 13 JAMA JAMA Rifampin prophylaxis for contacts of Haemophilus influenzae type b disease. 1043-5 Rifampin prophylaxis (20 mg/kg once daily for four days) was used in close contacts of children with Haemophilus influenzae type b (HIB) disease. Two hours after a dose, the concentration of rifampin in serum and saliva exceeded the minimum bactericidal (...) concentrations of organisms obtained from four of the carriers. In both a randomized prospective and an open study, nasopharyngeal carriage was eradicated in 37 (95%) of 39 contacts. No cases of serious H influenzae disease occurred in four to six months of follow-up. At the dose and treatment schedule used, rifampin was safe and effective for eradication of HIB carriage. Cox F F Trincher R R Rissing J P JP Patton M M McCracken G H GH Jr Granoff D M DM eng Clinical Trial Journal Article Randomized Controlled

JAMA1981

752. Successful treatment of naturally occurring influenza A/USSR/77 H1N1.

Successful treatment of naturally occurring influenza A/USSR/77 H1N1. 7007668 1981 04 24 1981 04 24 2016 10 17 0098-7484 245 11 1981 Mar 20 JAMA JAMA Successful treatment of naturally occurring influenza A/USSR/77 H1N1. 1128-31 Forty-five university students with proved influenza A/USSR/77 H1N1 infection were randomly treated with either amantadine hydrochloride (14 students), rimantadine hydrochloride (19 students), or placebo (12 students). By 48 hours after initiation of therapy, amantadine (...) and rimantadine recipients had significantly less fever and greater improvement compared with subjects given the placebo. Minor reversible CNS side effects at the end of the five-day course of therapy were observed in one third of the amantadine-treated subjects. However, both amantadine and rimantadine recipients returned to classes earlier and shed smaller amounts of virus than placebo recipients. Thus, both drugs exerted a notable therapeutic effect. Hence, during an influenza outbreak, five days

JAMA1981

753. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital.

Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. 83475 1979 03 24 1979 03 24 2015 06 16 0140-6736 1 8106 1979 Jan 06 Lancet (London, England) Lancet Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. 33-5 The boys of Christ's Hospital experienced outbreaks of influenza A in 1972 (A/England/42/72), in 1974 (A/Port Chalmers), and in 1976 (A/Victoria). In each outbreak, the protective (...) effect of inactivated influenza-A vaccine was limited to those boys, not already immune, who were vaccinated for the first time with the most up-to-date strain. Revaccination with the same strain did not increase the degree of protection, and revaccination with a later strain did not afford protection against subsequent challenge. The cummulative attack-rate in the three outbreaks was similar in all groups irrespective of vaccination history. These observations suggest that annual revaccination

Lancet1979

754. Prevention of Russian influenza by amantadine.

Prevention of Russian influenza by amantadine. 368354 1979 04 25 1979 04 25 2016 10 17 0098-7484 241 10 1979 Mar 09 JAMA JAMA Prevention of Russian influenza by amantadine. 1003-7 We tested the effectiveness of amantadine hydrochloride in prevention of illness and infection caused by Russian (h1n1) influenza. The trial lasted seven weeks and was double-blind and placebo controlled. The dosage used was 200 mg daily. Efficacy in prevention of serologically confirmed clinical influenza was 70.7 (...) for other subtypes of A influenza. Monto A S AS Gunn R A RA Bandyk M G MG King C L CL eng Clinical Trial Journal Article Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S. United States JAMA 7501160 0098-7484 BF4C9Z1J53 Amantadine AIM IM Adolescent Amantadine adverse effects pharmacology therapeutic use Child Clinical Trials as Topic Disease Outbreaks prevention & control Humans Influenza A virus drug effects Influenza, Human prevention & control Michigan Sex Factors 1979 3 9 1979 3 9 0 1

JAMA1979

755. Longer term effects of live influenza vaccine in patients with chronic pulmonary disease.

Longer term effects of live influenza vaccine in patients with chronic pulmonary disease. 68383 1977 07 29 1977 07 29 2015 06 16 0140-6736 1 8025 1977 Jun 18 Lancet (London, England) Lancet Longer term effects of live influenza vaccine in patients with chronic pulmonary disease. 1282-4 WRL 105 strain live influenza vaccine or placebo was given to patients with chronic bronchitis in a double-blind study. The twenty-one vaccinated and twenty-three placebo-treated patients made daily self (...) Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Antibodies, Viral 0 Influenza Vaccines AIM IM Adult Aged Antibodies, Viral analysis Bronchitis complications Chronic Disease Clinical Trials as Topic Follow-Up Studies Hemagglutination Inhibition Tests Humans Influenza Vaccines administration & dosage pharmacology Influenza, Human epidemiology prevention & control Middle Aged Orthomyxoviridae immunology Time Factors 1977 6 18 1977 6 18 0 1 1977 6 18 0 0 ppublish 68383 S0140-6736

Lancet1977

756. Influenza at Christ's Hospital: March, 1974.

Influenza at Christ's Hospital: March, 1974. 54631 1976 03 18 1976 03 18 2015 06 16 0140-6736 1 7951 1976 Jan 17 Lancet (London, England) Lancet Influenza at Christ's Hospital: March, 1974. 105-8 Boys in a boarding-school given inactivated influenza-A or influenza-B vaccine have been observed during a simultaneous outbreak of influenza due to A/Port Chalmers, B/Hong Kong, and B/Intermediate strains. Influenza-B vaccine conferred substantial protection, the attack-rates in boys given B vaccine (...) being 24% compared with 45% in a control group. A/Hong Kong vaccine, by preventing infection during the previous influenza A/England outbreak, left the boys vulnerable to influenza A/Port Chalmers. Influenza-A haemagglutination-inhibiting (H.I.) antibody acquired by natural infection was associated with more protection than H.I. antibody induced by vaccination. This difference was not seen with influenza-B H.I. antibody. Hoskins T W TW Davies J R JR Smith A J AJ Allchin A A Miller C L CL Pollock T M

Lancet1976